Hypogonadism, Male
Conditions
Brief summary
This is a prospective, non-blinded study of hypogonadal men with a history of testosterone therapy who became azoospermic or severely oligospermic and wish to avoid symptoms of hypogonadism during their recovery of spermatogenesis in an effort to establish paternity. The study will determine if Natesto can alleviate hypogonadal symptoms while preserving the recovery of spermatogenesis
Interventions
DRUGNatestoTM
Administering daily intranasal testosterone, Natesto nasal gel is available as a metered-dose pump. One pump actuation delivers 5.5 mg of testosterone
Sponsors
University of Florida
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Male between 18 and 64 years of age, with documented onset of testosterone induced hypogonadism with impaired semen parameters who are attempting to achieve a successful pregnancy. * Documented diagnosis of primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired). * Serum total testosterone \< 350 ng/dL based on 2 consecutive blood samples obtained 1-4 weeks apart between 6 and 10 AM following an appropriate washout of current androgen replacement therapy; with clinical symptoms of hypogonadism such as diminished energy and sexual function; and/or a decreased sperm count (\<20 million sperm/mL semen). * Discontinued current testosterone replacement treatment and completed a washout of 4 weeks following androgen treatment (excluding Testopel TM). Washout must be completed prior to collection of baseline serum testosterone samples to determine study eligibility. * Judged to be in good general health as determined by the principal investigator based upon the results of a medical history, physical examination, vital signs, and laboratory profile.
Exclusion criteria
* History of significant sensitivity or allergy to androgens, castor oil or product excipients. * Clinically significant findings in the pre-study examinations including abnormal breast examination requiring follow-up. * Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) or I-PSS score greater than 19 points. * Body mass index (BMI) equal to or greater than or equal to 40 kg/m2. * History of vasectomy. * Clinically significant abnormal laboratory value, in the opinion of the investigator, in serum chemistry, hematology, or urinalysis including but not limited to: 1. Baseline hemoglobin greater than 16 g/dL 2. Hematocrit less than 35% or greater than 50% 3. PSA greater than 4 ng/mL and age greater than 40 * History of seizures or convulsions, including febrile, alcohol or drug withdrawal seizures. * History of any clinically significant illness, infection, or surgical procedure within 4 weeks prior to study drug administration. * History of stroke or myocardial infarction within the past 5 years. * History of, or current or suspected, prostate or breast cancer. * History of diagnosed, severe, untreated, obstructive sleep apnea. * History of abuse of alcohol or any drug substance in the opinion of the investigator within the previous 2 years. * History of nasal disorders such as nasal polyps; nasal septal perforation; nasal surgery; nasal trauma resulting in nasal fracture within the previous 6 months or nasal fracture that caused a deviated anterior nasal septum; sinus surgery or sinus disease * Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 12 weeks prior to the start of treatment. * Inadequate venous access for collection of serial blood samples required for pharmacokinetic profiles. * Receipt of any investigational product within 4 weeks or within 5 half-lives prior to the start of treatment. * Inability to understand and provide written informed consent for the study. * Considered by the investigator or the sponsor-designated physician, for any reason, that the subject is an unsuitable candidate to receive Natesto.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in total motile sperm count | Baseline up to 26 weeks | Change in sperm count will be analyzed using the ANOVA. A change in \< ± 10% will be reject the null hypothesis. |
Countries
United States
Outcome results
None listed